New clinical study confirms that Bactiguard coated Foley catheters reduce infections in ICU
A recent independent and randomized clinical study confirms that Bactiguard-coated Foley catheters reduce catheter associated urinary tract infections in ICU patients.
The study was conducted at the King Fahad Hospital in Saudi Arabia and included 60 patients in the Intensive Care Unit (ICU), who were catheterized for at least 3 days. The incidence of catheter associated urinary tract infections was 90 percent lower for patients with Bactiguard-coated Foley catheters (BIP Foley) compared to patients with standard silicone Foley catheters (10 cases vs. 1 case, P = 0.006). The study is published in Urology Annals*.
”This is the first randomized study focused solely on ICU patients and we are pleased that it confirms previously published results” says Dr Dorota Johansson, Clinical and Research Director at Bactiguard.
* The study is now available at the Urology Annals webpage(and will be soon available at PubMed):
http://www.urologyannals.com/searchresult.asp?search=noble+metal+alloy&journal=X&entries=10&pg=1&I1.x=0&I1.y=0&sa=,UrolAnn_2016_8_4_423_192099
For further information, please contact:
Dorota Johansson, Clinical and Research Director, mobile: +46 706 54 31 71
About Bactiguard
Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of Foley catheters, central venous catheters and endotracheal tubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 60 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com
Tags: